Iris Allajbeu

Iris Allajbeu

Auto-generated profile, based on publicly available information

Iris Allajbeu

Department of Radiology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Radiology
Verified
Journal Article
Closed access
MNMuzna Nanaa
Muzna Nanaa
VGVaishnavi O. Gupta
Vaishnavi O. Gupta
SHSarah E. Hickman
Sarah E. Hickman
IAIris Allajbeu
Iris Allajbeu
NPNicholas R. Payne
Nicholas R. Payne
FGFiona J. Gilbert
Fiona J. Gilbert
An artificial intelligence algorithm accurately detected one-quarter of interval cancers on screening mammograms and accurately located three-quarters of them, which could result in earlier detection of breast cancer.

23 June 2021 in Current Breast Cancer Reports
Verified
Journal Article
Open access
PDF file
IAIris Allajbeu
Iris Allajbeu
SHSarah E Hickman
Sarah E Hickman
NPNicholas Payne
Nicholas Payne
PMPenelope Moyle
Penelope Moyle
KTKathryn Taylor
Kathryn Taylor
FGFiona J Gilbert
Fiona J Gilbert
Purpose of Review: Automated breast ultrasound (ABUS) is a three-dimensional imaging technique, used as a supplemental screening tool in women with dense breasts. This review considers the technical aspects, pitfalls, and the use of ABUS in screening and clinical practice, together with new developments and future perspectives. Recent Findings: ABUS has been approved in the USA and Europe as a screening tool for asymptomatic women with dense breasts in addition to mammography. Supplemental US screening has high sensitivity for cancer detection, especially early-stage invasive cancers, and reduces the frequency of interval cancers. ABUS has similar diagnostic performance to handheld ultrasound (HHUS) and is designed to overcome the drawbacks of operator dependence and poor reproducibility. Concerns with ABUS, like HHUS, include relatively high recall rates and lengthy reading time when compared to mammography. ABUS is a new technique with unique features; therefore, adequate training is required to improve detection and reduce false positives. Computer-aided detection may reduce reading times and improve cancer detection. Other potential applications of ABUS include local staging, treatment response evaluation, breast density assessment, and integration of radiomics. Summary: ABUS provides an efficient, reproducible, and comprehensive supplemental imaging technique in breast screening. Developments with computer-aided detection may improve the sensitivity and specificity as well as radiologist confidence and reduce reading times, making this modality acceptable in large volume screening centers.

16 July 2025 in European Journal of Radiology
Verified
Journal Article
Open access
JSJavier Azcona Sáenz
Javier Azcona Sáenz
PBPascal A.T. Baltzer
Pascal A.T. Baltzer
IAIris Allajbeu
Iris Allajbeu
ARAllison Rose
Allison Rose
EAErkin Aribal
Erkin Aribal
TNThiemo J.A. van Nijnatten
Thiemo J.A. van Nijnatten
To perform an international survey among global expert breast radiologists regarding contrast-enhanced mammography (CEM) on the topic of reimbursement strategies. An online questionnaire on CEM reimbursement strategies was distributed to 29 selected global expert breast radiologists regarding CEM. Hospital information, CEM implementation, estimated costs, reimbursement availability, registration and declaration codes, as well as personal opinions on CEM reimbursement, were collected. Replies were analyzed using descriptive and non-parametric statistics. Twenty out of 29 global expert breast radiologists regarding CEM responded to this survey. All respondents had implemented CEM at their hospitals between 2011 and 2024 and offered CEM for clinical/diagnostic indications, CEM price ranges were lower than MRI at all but two sites. Sixty percent of hospitals (12/20) reported receiving reimbursement for CEM. The remaining 40% declared not receiving reimbursement, citing reasons such as coverage by department budget, lack of dedicated billing code, or absence of reimbursement by the national healthcare system and/or insurance providers. Among the 12 hospitals receiving reimbursement, 67% (8/12) obtained full reimbursement for all components of CEM, and 75% (9/12) for all indications. Reimbursement sources varied by hospital type, with public and university hospitals mainly publicly funded, and private hospitals relying on insurance or patient payments. Most respondents (75%, 15/20) reported that no dedicated national reimbursement code for CEM currently exists. Of these respondents, 53% (8/15) used the FFDM code. Most hospitals lacked separate codes for the contrast medium (60%, 9/15) or its intravenous injection (93.3%, 14/15). Among hospitals without a national code, 73% (11/15) were aware of efforts to establish one. Although nearly half of the participants (45%, 9/20) faced reimbursement challenges, 65% (13/20) stated that reimbursement strategies did not affect their CEM adoption. Substantial heterogeneity in CEM reimbursement strategies exist, with most hospitals securing full coverage through alternative strategies until dedicated national reimbursement codes are established.

16 January 2026 in Insights into Imaging
Verified
Journal Article
Open access
PDF file
IAIris Allajbeu
Iris Allajbeu
KCKate R. Charnley
Kate R. Charnley
YYYuyin Yang
Yuyin Yang
JFJohanna Field-Rayner
Johanna Field-Rayner
KMKirsten Morris
Kirsten Morris
FGFiona J. Gilbert
Fiona J. Gilbert
Objectives: To evaluate patient acceptance and feedback regarding supplemental imaging modalities: automated whole-breast ultrasound (ABUS), contrast-enhanced mammography (CEM), and abbreviated breast MRI (AB-MRI) within the BRAID (Breast Screening: Risk Adaptive Imaging for Density) trial. Materials and methods: An adapted Testing Morbidities Index questionnaire was utilised to capture participant experiences and perceptions (January-April 2024) related to AB-MRI, ABUS and CEM. Likert-scale questions assessed discomfort, anxiety, and overall satisfaction for each imaging modality, while thematic analysis was applied to free-text patient feedback. Additionally, reasons for withdrawal were recorded for each modality. Results: Among 159 women providing feedback, 57/159 (35.8%) underwent ABUS, 52/159 (32.7%) CEM, and 50/159 (31.5%) AB-MRI. Acceptability of ABUS, CEM and AB-MRI was rated similarly to mammography by 71/159 (64.8%) of these respondents, with 72/159 (45.3%) considering them superior. Mild-to-moderate discomfort due to breast compression was reported for ABUS and CEM, whereas AB-MRI resulted in the least discomfort. Pre-procedural anxiety was observed across all imaging modalities, particularly with contrast-enhanced techniques; however, experiences were generally well-tolerated. Effective communication and pre-test information reduced anxiety levels, with most participants willing to repeat the procedures. 151/984 (15.3%) withdrawals in BRAID were due to adverse patient experiences, with contrast-enhanced techniques accounting for most of these withdrawals (CEM: 69/151, 45.7%; AB-MRI: 66/151, 43.7%; ABUS: 12/151, 7.9%). The main reasons for withdrawal were unhappiness with the allocated imaging arm and discomfort or anxiety during the procedure. Conclusion: Supplemental imaging modalities are generally well-accepted by patients with benefit throughout gained by clear communication and preparedness. Critical relevance statement: Feedback from a subgroup of women participating in the BRAID trial shows that supplemental imaging alongside routine screening is well-accepted. Clear communication and empathetic care further improve acceptance, supporting a shift toward personalised breast cancer screening for women with dense breasts. Key Points: Understanding women’s imaging experiences is essential for optimising breast screening practices. Acceptability of supplemental imaging was rated similar to or better than mammography by most participants. Clear, empathetic communication reduced anxiety and improved experience with contrast-enhanced imaging. Graphical